fbpx

INOVIO completes first phase of COVID-19 vaccine trial

INOVIO, the Doylestown-based pharmaceutical company, has completed the first phase of its clinical trial for a COVID-19 vaccine. All 40 healthy volunteers in the trial have now received their first dose, INOVIO says.

Interim immune responses and safety results are expected in late June, the company says. The trial’s volunteers are enrolled at sites at the University of Pennsylvania in Philadelphia and a clinic in Kansas City, Missouri.

The volunteers will receive two doses of INO-4800 in total, four weeks apart. INOVIO is on track to deliver a million doses of a COVID-19 vaccine by year’s end. The company previously created a successful vaccine for a related coronavirus that causes Middle East Respiratory Syndrome, or MERS.

Dawn Ouellette Nixon
Dawn Ouellette Nixon is a career journalist who believes that good journalism can change the world. As the health care reporter, she covers everything from small town medicine to big pharma. You can also find her chasing a good business story in Berks County. She can be reached at dnixon@bridgetowermedia.com. or 610-807-9619, extension 4118.

Business Journal Events

Diversity, Equity, and Inclusion Summit

Tuesday, March 30, 2021
Diversity, Equity, and Inclusion Summit

Women of Influence Awards

Monday, May 03, 2021
Women of Influence Awards

Health Care Heroes

Tuesday, June 01, 2021
Health Care Heroes

Health Care Summit

Friday, August 06, 2021
Health Care Summit
/* code for sifitag */